<DOC>
	<DOCNO>NCT02911792</DOCNO>
	<brief_summary>The investigator propose treat newly diagnose , hyperfiltering T2DM patient without microalbuminuria dapagliflozin metformin 4 month . The metformin-treated group serve control improved glycemic control , since investigator show insulin therapy normalize A1c reduce hyperfiltration kidney size T1DM patient .</brief_summary>
	<brief_title>Effect Farxiga Renal Function Size Type 2 Diabetic Patients With Hyperfiltration</brief_title>
	<detailed_description>Hyperfiltration characteristic feature experimental model diabetes causally related increase intraglomerular pressure . In newly diagnose diabetic patient , type 1 type 2 , hyperfiltration enlarge kidney size commonly observe , hemodynamic/anatomic abnormality associate increase risk development diabetic nephropathy . In poorly control diabetic individual , filter load glucose markedly increase glucose - sodium - reabsorption SGLT2 transporter proximal tubule augment . As consequence sodium delivery macula densa reduce , make kidney think perfuse result afferent renal arteriolar vasodilation . The efferent arteriole hyperfiltrating diabetic kidney also hypersensitive angiotensin II despite absence systemic RAS activation . The net result hemodynamic change increase intraglomerular pressure hyperfiltration . Further , angiotensin potent growth factor contribute increase size individual glomerulus total kidney size . Since intraglomerular pressure relate radius ( r3 ) Law LaPlace , increase glomerular size also contribute hyperfiltration . Based upon precede sequence , follow drug block glucose , along sodium , reabsorption proximal tubule would enhance sodium delivery macula densa , cause afferent renal arteriolar constriction , reduce intraglomerular pressure/hyperfiltration , decrease kidney size . In hyperfiltering diabetic patient microalbuminuria , investigator also would expect microalbuminuria decrease . Consistent scenario , animal study document acute chronic inhibition SGLT2 decrease hyperfiltration prevents diabetic nephropathy . A recent study hyperfiltering type 1 diabetic patient treat empagliflozin provide additional support tubular glomerular feedback hypothesis . The investigator propose treat newly diagnose , hyperfiltering T2DM patient without microalbuminuria dapagliflozin metformin 4 month . The metformin-treated group serve control improved glycemic control , since investigator show insulin therapy normalize A1c reduce hyperfiltration kidney size T1DM patient</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Newly diagnose , drug naïve , hyperfiltering normofiltration patient type 2 diabetes mellitus ( T2DM ) Hyperfiltration define GFR &gt; 135 ml/min•1.73m2 Normofiltration GFR = 90134 ml/min•1.73m2 BMI = 2045 kg/m2 HbA1c = 7.5 % 12 % Willingness participate 16 week study protocol Hematocrit &gt; 34 % GAD antibody negative BP &lt; 145/90 mmHg &gt; 300 mg/day albumin excretion Ingestion medication know interfere reninangiotensin system renal function , include diuretic therapy Hospitalization unstable angina , history recent macrovascular ( MI/stroke/TIA/ACS ) disease , coronary artery revascularization ( within 2 month prior enrollment ) Proliferative diabetic retinopathy History cancer major organ system disease New York Heart class IIIV heart failure Severe hepatic insufficiency and/or significant abnormal liver function define aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN total bilirubin &gt; 2.0 mg/dL ( 34.2 µmo/L ) Treatment steroid , beta blocker , alpha blocker , antiobesity drug Pregnant nursing mother Premenopausal females practice acceptable contraceptive method Participation another trial investigational drug within 30 day Alcohol drug abuse within precede 6 month Any condition , psychiatric medical , opinion investigator would interfere successful completion study Orthostatic hypotension ( &gt; 15/10 mmHg decrease upon stand 3 minute ) Positive serologic evidence current infectious liver disease include Hepatitis B viral antibody IGM , Hepatitis B surface antigen , Hepatitis C virus antibody HIV Volume deplete patient Estimated glomerular filtration rate &lt; 60 mL/min•1.73m2 . Patients risk volume depletion due coexist condition concomitant medication , loop diuretic careful monitoring volume status</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hyperfiltering</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>